Comparative Pharmacology
Head-to-head clinical analysis: LYMPHOSEEK KIT versus POSLUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYMPHOSEEK KIT versus POSLUMA.
LYMPHOSEEK KIT vs POSLUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
PSMA-targeted radiotherapeutic agent; emits beta radiation causing DNA damage and cell death in PSMA-expressing cells.
Pre-dose: 20 mcg (0.5 mL) intradermally followed by 0.5 mL subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 mL (20 mcg) subcutaneously.
1.85 MBq (0.05 mCi)/kg intravenously as a single injection, followed by PET imaging approximately 60 minutes post-injection.
None Documented
None Documented
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Terminal elimination half-life: approximately 25–30 minutes for [68Ga]Ga-PSMA-11; rapid clearance from blood pool due to renal and hepatobiliary elimination.
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Renal: 0% (not significantly eliminated via kidneys); Biliary/Fecal: predominantly eliminated via hepatobiliary system with fecal excretion of intact complex and metabolites, though precise % not established for human.
Category C
Category C
Radiopharmaceutical Diagnostic Agent
Radiopharmaceutical Diagnostic Agent